Navigation Links
European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion

TORONTO, Nov. 6, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the maturing European interventional cardiology (IC) device market will be supported by the uptake of complex procedures as well as adoption of innovative premium-priced products. Although percutaneous coronary interventions (PCIs) are well accepted in Europe, the applications for these treatments are continuing to expand, supporting total procedure volumes. For example, more physicians are now performing PCIs to treat chronic total occlusions (CTOs), especially given that companies such as ASAHI INTECC and Abbott Laboratories have designed accessory devices specifically for this purpose.

(Logo: )

The market will also be supported by growing acceptance of some premium-priced devices. For example, physicians are very enthusiastic about the potential for bioresorbable vascular scaffolds (BVS), which the body gradually absorbs, leaving no permanent hardware. Similarly, the European Society of Cardiology has recently released favorable recommendations for using drug-coated balloons (DCBs) for in-stent restenosis, as well as for using fractional flow reserve (FFR) guidewires.

"While the use of these products is growing, the extent of adoption will be determined in the next few years," said MRG Analyst Leila Bautista. "Right now, the high cost of these products is prohibitive for many facilities in Europe, and reimbursement is not ideal. There is no significant competitive pricing pressure either because the technology is so new that not that many companies offer these products yet. Nonetheless, if reimbursement improves or these products become more affordable, they have considerable potential in Europe."

The German and United Kingdom markets will have the most favorable environment for competitors through 2022 because of higher acceptance of premium-priced devices and more favorable reimbursement, respectively. By contrast, Spain and Italy have been most severely affected by the economic situation in Europe, resulting in hindered PCI volumes and drastic price declines. France lies in between, with its IC device market remaining fairly stable.

Millennium Research Group's European Markets for Interventional Cardiology Devices 2014 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, accessory devices and intravascular imaging catheters and press guidewires in France, Germany, Italy, Spain and the United Kingdom.

About Millennium Research Group
Millennium Research Group (, a Decision Resources Group company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group

Alex Jablokow
Millennium Research Group

SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HighPoint Solutions and InnoPeritus Partner to Provide Unprecedented Consultative Services in the European Life Sciences Market
2. US and European Regulators Accept for Review OMS302 Marketing Applications
3. Varians Calypso Tumor Tracking System Used in Lung, Stomach and Prostate Cancer Treatments at Leading European Cancer Center
4. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
7. Glysure Appoints Justine McQuillan as European Director of Clinical Affairs
8. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
9. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
10. European Market for Remote Patient Monitoring Applications
11. Harlan Laboratories Continues Strategic Growth with Expansion of South European Services Facility
Post Your Comments:
(Date:10/12/2015)... 2015 About epilepsy --> ... of brain disorders manifested by benign to severe, disabling, ... from brain malformations and tumors to meningitis, high-risk pregnancies, ... the disease is unidentified, as is witnessed in the ... An imbalance between the inhibitory and excitatory signals of ...
(Date:10/12/2015)... Elbit Imaging Ltd. ("EI" or the ... board of directors approved a program to repurchase up to ... H Notes and Series I Notes, which are traded on ... the Company will have a significant preference to the purchase ... to time in the open market on the Tel Aviv ...
(Date:10/12/2015)... 2015 A new computer program that analyzes ... whether they will develop effective language skills within two ... in the journal Brain and Behavior . ... the journal,s Oct. 12 online edition, researchers at Cincinnati ... how specific regions of the brain respond to auditory ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Doulagivers is O'Brien's licensed ... and End of Life Doula Training. A Doulagiver is a non-medical person ... emotionally. Based on her #1 International bestselling book Creating Positive Passings & ...
(Date:10/12/2015)... ... October 13, 2015 , ... North American Tool Corporation ... the 2015 IBC National Meeting in Rosemont, IL on October 4th. ... and standards of excellence that customers have come to expect from members of IBC’s ...
(Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... ... on August 19, 2015, high school aged female athletes, particularly in the ... potentially sidelining repetitive motion and mechanical overuse injuries than male peers in the ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... hypnosis by individuals who lack professional education and clinical training in a health ... for a variety of purposes such as: losing weight, managing pain, or stopping ...
(Date:10/12/2015)... ... ... The Horizon Foundation for New Jersey has awarded $846,600 in grants to ... quality of life in the Garden State. The grants, representing the second round of ... charitable arm of Horizon Blue Cross Blue Shield of New Jersey, the Horizon Foundation ...
Breaking Medicine News(10 mins):